CNBC April 13, 2023
Key Points
– A complicated legal fight over the Food and Drug Administration’s approval of the abortion pill mifepristone could stifle innovation in the biopharma industry.
– If courts affirm U.S. District Judge Matthew Kacsmaryk’s decision to suspend the FDA’s approval, it could make way for more lawsuits challenging the agency’s decision-making related to existing and future drugs.
– That could deter investments in the development of life-changing drugs, biopharma companies and experts in law and economics said.
A messy legal fight over the Food and Drug Administration’s approval of the abortion pill mifepristone poses risks to the biopharma industry that go beyond the single drug.
If a subsequent decision tosses out the pill’s approval, it could potentially stifle...
Today's Sponsors
Today's Sponsor